HomeLarge Type Edition
HOME ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Services
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
PubMed
Right arrow PubMed Citation
The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 59:M139-M142 (2004)
© 2004 The Gerontological Society of America

EDITORIAL

The Metabolic Syndrome and Aging

John E. Morley

Geriatric Research, Education, and Clinical Center, St. Louis VA Medical Center, Missouri. Division of Geriatric Medicine, Saint Louis University, St. Louis, Missouri.

In 1966, Camus first described the concept of the metabolic syndrome (1). From 1988 onwards, the importance of the metabolic syndrome was popularized by Reaven (2). The metabolic syndrome consists of a deadly quintet of factors, namely diabetes, hypertension, hyperuricemia, lipid abnormalities, and alterations in thrombotic potential, that are associated with hyperinsulinemia and insulin resistance. The metabolic syndrome is directly related to increased atherogenesis and death from myocardial infarction. The metabolic syndrome is directly related to the accumulation of visceral adiposity in middle age associated with overeating and a decline in exercise. In addition, there appears to be a genetic predisposition to developing the metabolic syndrome. The metabolic syndrome could be conceived as the "couch potato" syndrome (Figure 1)! It has been estimated that 15% to 20% of persons aged over 70 years have the metabolic syndrome.



View larger version (36K):
[in this window]
[in a new window]
  		Figure 1. Metabolic Syndrome: The Deadly Quintet (Camus 1966; Reaven 1988). The components of the metabolic syndrome

 
Banks and colleagues (3) studied a subset of wild baboons (Papio cynocephalus) that foraged from a trash heap in the Kenyan savannah. Some of this tribe of baboons developed hyperleptinemia, hyperinsulinemia, hyperglycemia, elevated insulin/glucose ratios, and increased cholesterol. Others in the same tribe developed hypercholesterolemia but none of the signs of insulin resistance. This demonstrated the importance of the interaction of genetic predisposition with the environment in the pathogenesis of the metabolic syndrome.

Besides insulin, two other hormones have been associated with the development of the metabolic syndrome. These are leptin and adiponectin. Both are peptide hormones produced from adipose tissue. Leptin levels closely follow the amount of total adiposity (4,5). Leptin produces anorexia and increased metabolism, thus attempting to decrease the increased adiposity (6). Testosterone decreases leptin levels in males and leads to a decline in body fat (7,8). Thus, the age-related decline in testosterone in males may play a role in the pathogenesis of the metabolic syndrome (9). With increasing obesity, resistance to the effects of leptin occurs. This resistance appears to be due to hypertriglyceridemia.

Adiponectin has been shown to enhance insulin sensitivity and decrease triglycerides (10). Low levels of adiponectin are closely associated with the development of insulin resistance. Trunkal fat is associated with increased cytokines such as interleukin-6 and tumor-necrosis factor {alpha} (11). These two cytokines play a role in the development of insulin resistance. Testosterone inhibits the production of interleukin-6, again supporting a minor role for the andropause in the development of the metabolic syndrome (12).

Numerous recent studies have shown that hypertension is especially lethal in diabetics. Both the SHEP (Systolic Hypertension in Elderly Persons) and the Syst-Eur Trial found an almost doubling of mortality risks in older diabetics with systolic hypertension (13,14). The UKPDS (United Kingdom Prospective Diabetes Study) found that treating blood pressure produced better risk reduction than did treating diabetes (15). In the HOPE (Heart Outcomes and Prevention Evaluation) and CAPP (Captopril Prevention Project) trials, angiotensin-converting enzyme inhibitors had a better effect on lowering cardiovascular events in diabetics compared with nondiabetics (16,17). In addition, in the SCOPE (Study on Cognition and Prognosis in the Elderly) trial angiotensin receptor blockers decreased new onset diabetes by 20% (18). Coronary artery disease can be characterized as the diabetic's sword of Damocles. It is clear that diabetics require aggressive treatment to prevent atherosclerosis.

The DIGAMI (diabetes mellitus, insulin glucose infusion in acute myocardial infarction) studies examined 620 persons with diabetes who developed a myocardial infarction (19). The mean age was 68 years. They provided intensive glucose-lowering therapy in all participants with a glucose equal or greater than 11 mmol/L. In a 3.4 year follow-up, they found a reduction in mortality, with only 9 persons being the number needed to treat to prevent 1 additional death.

In this issue of the Journals, Rasgon and Jarvik (20) suggest that dementia and depression should be considered, in some cases, to be due to the metabolic syndrome. A number of commentators have taken issue with some of their hypothesis while agreeing with other components (21–24). Recently, in-depth reviews of the pathogenesis of dementia and its associated behaviors (25–27), as well as of depression (28), have appeared in the Journals.

The causes of cognitive decline in diabetes are complex and multifactorial. It is clear that diabetes in older persons is associated with a worse cognitive function compared with those who have normal cognition (29,30). Gregg and colleagues (31) followed 682 women aged 72 years with diabetes and found a two-fold increase in cognitive impairment over this period. Numerous studies have shown that not only do older diabetics have cognitive impairment, but that they also have excess functional decline (32–38).

A number of studies have shown that hyperglycemia per se produces cognitive dysfunction and that cognition is improved when glucose is lowered (39–41). Also, persons with the metabolic syndrome are more likely to have small infarcts and develop vascular dementia, (42–44) as are persons with hypertension (45–48). Glucoregulatory hormones such as amylin (49) and glucagon-like peptide I (50) are modulators of memory.

As shown in a forthcoming article by Zamboni and colleagues leptin levels are closely related to the metabolic syndrome in older women (51). Leptin receptor-deficient animals have impaired spatial memory and long-term potentiation in CA1 of the hippocampus, suggesting that leptin is a powerful memory enhancer (52).

In Type II diabetes, elevated triglycerides are associated with poor performance on the digit symbol substitution test, digit span backward test, and reaction time (53). In another study, elevated triglycerides were associated with poor semantic memory (54). Reducing hypertriglyceridemia with gerrifibrozal improved both cerebral blood flow and function on the cognitive capacity screening examination (55). Plasma high-density lipoprotein levels are correlated with cognition in persons with exceptional longevity (56). Elias and colleagues (57) found that obesity and hypertension are independently related to impaired cognition on a battery of cognitive tests. These studies support the hypothesis that cognitive dysfunction should be considered a part of or a consequence of the metabolic syndrome.

The concept that the metabolic syndrome directly leads to Alzheimer's disease is intriguing. Clearly, small vascular infarcts can lead to cytokine production, which may stimulate beta-amyloid production (58), and low testosterone levels that occur in diabetes may be associated with overproduction of ß-amyloid (59,60). ß-amyloid overproduction appears central to the pathogenesis of Alzheimer's disease, not only by directly decreasing memory (61–63) but also by leading to the overproduction of free radicals (64). Hyperglycemia and hypertriglyceridemia can interact with the amnestic effects of beta-amyloid to cause a more rapid decline in cognition, and diabetes accelerates free radical production.

Depression has been shown to lead to poor outcomes in older diabetics (65). This is predominantly due to the poor compliance associated with depression. Persons with depression often have elevated cortisol levels, which can lead to hyperglycemia and hypertension (66). Persons who have cerebral vascular accidents are more likely to suffer major depression (28). Persons with depression have poorer outcomes when they have a myocardial infarction and are more likely to have a subsequent myocardial infarction (28). Depression is obviously closely related to the metabolic syndrome, but which is the chicken and which is the egg remains uncertain.

While some of the "merchants of immortality" continue to search for the Holy Grail of longevity (67–69), it is clear that the physician who practices evidence-based medicine and avoids errors already has many of these tools in his or her grasp (70–72). Diabetes accelerates damage to the DNA (73). It is now becoming clear that rigorous treatment of the metabolic syndrome when it first emerges in middle age represents not only a key to life prolongation, but also to extended number of quality-adjusted life years that a person will experience. As has so often been pointed out in the Journals, exercise, particularly resistance exercise, represents an important component of the treatment to slow aging by reducing the prevalence of the metabolic syndrome and decreasing cognitive and depressive syndromes (74–77). As always, the appropriate care of older persons requires an interaction of "high touch" and "high tech."

Acknowledgments

Address correspondence to John E. Morley, MB, BCh, Division of Geriatric Medicine, Saint Louis University School of Medicine, 1402 S. Grand Blvd., M238, St. Louis, MO 63104. E-mail: morley{at}slu.edu

References

  1. Camus JP.. Revue du Rhumatisme et des Maladies Osteo-Articulaires.. 1966;33:10-14.
  2. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Ann Rev Med.. 1993;44:121-131.[Medline]
  3. Banks WA, Altmann J, Sapolsky RM, Phillips-Controy JE, Morley JE. Serum leptin levels as a marker for a syndrome X-like condition in wild baboons. J Clin Endocrinol Metab.. 2003;88:1234-1240.[Abstract/Free Full Text]
  4. Perry HM, Morley JE, Horowitz M, Kaiser FE, Miller DK, Wittert G. Body composition and age in African-American and Caucasian women—relationship to plasma leptin levels. Metab Clin Exper.. 1997;46:1399-1405.[Medline]
  5. Baumgartner RN, Ross RR, Waters DL, et al. Serum leptin in elderly people: associations with sex hormones, insulin, and adipose tissue volumes. Obesity Res.. 1999;7:141-149.[Medline]
  6. Morley JE, Perry HM, III, Baumgartner RP, Garry PJ. Leptin, adipose tissue and aging—is there a role for testosterone? J Gerontol Biol Sci.. 1999;54A:B108-B109.
  7. Sih R, Morley JE, Kaiser FE, Perry HM, III, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab.. 1997;82:1661-1667.[Abstract/Free Full Text]
  8. Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol Med Sci.. 2003;58A:618-625.
  9. Morley JE, Perry HM. Androgen treatment of male hypogonadism in older males. J Steroid Biochem Molecul Biol.. 2003;85:367-373.
  10. Mannucci E, Ognibene A, Cremasco F, et al. Plasma adiponectin and hyperglycaemia in diabetic patients. Clin Chem Lab Med.. 2003;41:1131-1135.[Medline]
  11. Krakoff J, Funahashi T, Stehouwe CDA, et al. Inflammatory markers, adiponectin and risk of type 2 diabetes in the Pima Indian. Diabetes Care.. 2003;26:1745-1751.[Abstract/Free Full Text]
  12. Lambert CP, Sullivan DH, Evans WJ. Effects of testosterone replacement and/or resistance training on interleukin-6, tumor necrosis factor alpha, and leptin in elderly men ingesting megestrol acetate: A randomized controlled trial. J Gerontol Med Sci.. 2003;58A:165-170.
  13. Curb JD, Pressel SL, Cutler JA, et al. Ramipril and the development of diabetes. JAMA.. 2001;286:1882-1885.[Abstract/Free Full Text]
  14. Safar M, Thijs L, Staessen JA. Syst-Eur trial: benefits of nitrendipine in the type 2 diabetic hypertensive patients [French]. Arch des Maladies du Coeur et des Vaisseaux.. 2003;96:768-771.
  15. Adler AI, Stratton IM, Neil HAW, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Brit Med J.. 2000;321:412-419.[Abstract/Free Full Text]
  16. Yasuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BHR, Zinman B. Ramipril and the development of diabetes. JAMA.. 2001;286:1882-1885.
  17. Fournier A, Ghitu A, Darabont R, et al. Duality of angiotensin II receptors and stroke and cancer risk: is there a link? [French]. Presse Medicale.. 1999;28:918-922.
  18. Lithell H, Hansson L, Skoog I, et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertension.. 2003;21:875-886.[Medline]
  19. Davies MJ, Lawrence IG. Digami (diabetes mellitus, insulin glucose infusion in acute myocardial infarction): theory and practice. Diab Obesity Metab.. 2002;4:289-295.
  20. Rasgon N, Jarvik L. Insulin resistance, affective disorders, and Alzheimer's Disease: review and hypothesis. J Gerontol Med Sci.. 2004;59A:178-183.
  21. Vellas B, Sinclair A. Commentary. Insulin resistance, obesity, and the risk of neurodegenerative diseases [On Rasgon and Jarvik's "Insulin resistance, affective disorders, and Alzheimer's disease: review and hypothesis"]. J Gerontol Med Sci.. 2004;59A:189.
  22. Vischer U, Szanto I, Michel JP. Commentary. The association between insulin resistance, depression and dementia [On Rasgon and Jarvik's "Insulin resistance, affective disorders, and Alzheimer's disease: review and hypothesis"]. J Gerontol Med Sci.. 2004;59A:189-191.
  23. Banks WA. Commentary [On Rasgon and Jarvik's "Insulin resistance, affective disorders, and Alzheimer's disease: review and hypothesis"]. J Gerontol Med Sci.. 2004;59A:184-185.
  24. Lyketsos CG, Lee H. Commentary. Insulin resistance as a link between affective disorder and Alzheimer's disease: a hypothesis in need of further refinement [On Rasgon and Javik's "Insulin resistance, affective disorders, and Alzheimer's disease: review and hypothesis"]. J Gerontol Med Sci.. 2004;59A:185-187. Newcomer J. Commentary [On Rasgon and Jarvik's "Insulin resistance, affective disorders, and Alzheimer's disease: review and hypothesis"]. J Gerontol Med Sci.. 2004;59A:187-189.
  25. Banks WA, Morley JE. Memories are made of this: Recent advances in understanding cognitive impairments and dementia. J Gerontol Med Sci.. 2003;58A:314-321.
  26. Grossberg GT, Desai AK. Management of Alzheimer's disese. J Gerontol Med Sci.. 2003;58A:331-353.
  27. Volicer L, Hurley AC. Management of behavioral symptoms in progressive degenerative dementias. J Gerontol Med Sci.. 2003;58A:837-845.
  28. Blazer DG. Depression in late life: review and commentary. J Gerontol Med Sci.. 2003;58A:249-265.
  29. Bruce DG, Casey GP, Grange V, et al. Cognitive impairment, physical disability and depressive symptoms in older diabetic patients: the Fremantle cognition in diabetes study. Diabetes Res Clin Pract.. 2003;61:59-67.[Medline]
  30. Coker LH, Shumaker SA. Type 2 diabetes mellitus and cognition—an understudied issue in women's health. J Psychosomatic Res.. 2003;54:129-139.[Medline]
  31. Gregg EW, Yaffe K, Cauley JA, et al. Is diabetes associated with cognitive impairment and cognitive decline among older women? Arch Intern Med.. 2000;160:174-180.[Abstract/Free Full Text]
  32. Ottenbacher KJ, Ostir GV, Peek MK, Goodwin JS, Markides KS. Diabetes mellitus as a risk factor for hip fracture in Mexican American older adults. J Gerontol Med Sci.. 2002;57A:M648-M653.
  33. Nilsson E, Fastbom J, Wahlin A. Cognitive functioning in a population-based sample of very old non-demented and non-depressed persons: the impact of diabetes. Arch Gerontol Ger.. 2002;35:93-105.
  34. Mooradian AD. Central nervous system complications of diabetes mellitus—a perspective from the blood-brain barrier. Brain Res Rev.. 1997;23:210-218.[Medline]
  35. Morley JE, Perry HM, Miller DK. Something about frailty. J Gerontol Med Sci.. 2002;57A:M698-M704.
  36. Miller DK, Lui LYL, Perry HM, Kaiser FE, Morley JE. Reported and measured physical functioning in older inner-city diabetic African Americans. J Gerontol Med Sci.. 1999;54A:M230-M236.
  37. Morley JE. An overview of diabetes mellitus in older persons. Clin Geriatr Med.. 1999;15:211-224.[Medline]
  38. Rodriguez-Saldana J, Morley JE, et al. Diabetes mellitus in a subgroup of older Mexicans: Prevalence, association with cardiovascular risk factors, functional and cognitive impairment, and mortality. J Am Geriatr Soc.. 2002;50:111-116.[Medline]
  39. Nguyen HT, Black SA, Ray LA, Espino DV, Markides KS. Predictors of decline in MMSE scores among older Mexican Americans. J Gerontol Med Sci.. 2002;57A:M181-M185.
  40. Mooradian AD, Perryman K, Fitten J, Kavonian GD, Morley JE. Cortical function in elderly non-insulin dependent diabetic patients. Behavioral and electrophysiologic studies. Arch Intern Med.. 1988;148:2369-2372.[Abstract/Free Full Text]
  41. Flood JF, Mooradian AD, Morley JE. Characteristics of learning and memory in streptozocin-induced diabetic mice. Diabetes.. 1990;39:1391-1398.[Abstract]
  42. Ostir GV, Raji MA, Ottenbacher KJ, Markides KS, Goodwin JS. Cognitive function and incidence of stroke in older Mexican Americans. J Gerontol Med Sci.. 2003;58A:531-535.
  43. Aronow WS, Ahn C, Gutstein H. Reduction of new coronary events and new atherothrombotic brain infarction in older persons with diabetes mellitus, prior myocardial infarction, and serum low-density lipoprotein cholesterol >=125 mg/dl treated with statins. J Gerontol Med Sci.. 2002;57A:M747-M750.
  44. Aronow WS, Ahn C. Risk factors for new atherothrombotic brain infarction in older Hispanic men and women. J Gerontol Med Sci.. 2002;57A:M61-M63.
  45. Hajjar RR. Commentary on "Embracing complexity: a consideration of hypertension in the very old [Commentary] ?? J Gerontol Med Sci.. 2003;58A:661-662.
  46. Goodwin JS. Embracing complexity: a consideration of hypertension in the very old. J Gerontol Med Sci.. 2003;58A:653-658.
  47. Thomas DR. The struggle to relate epidemiology to real people [Commentary]. J Gerontol Med Sci.. 2003;58A:667-668.
  48. Aronow WS. What is the appropriate treatment of hypertension in elders? J Gerontol Med Sci.. 2002;57A:M483-M486.
  49. Flood JF, Morley JE. Differential effects of amylin on memory processing using peripheral and central routes of administration. Peptides.. 1992;13:577-580.[Medline]
  50. During MJ, Cao L, Zuzga DS, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nature Med.. 2003;9:1173-1179.[Medline]
  51. Zamboni M, Zoico E, Fantin F, et al. Relation between leptin and the metabolic syndrome in elderly women. J Gerontol Med Sci. In press.
  52. Li XL, Aou S, Oomura Y, Hori N, Fukunaga K, Hori T. Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents. Neuroscience.. 2002;115:607-615.
  53. Helkala EL, Niskanen L, Viinamaki H, Partanen J, Uusitupa M. Short-term and long-term memory in elderly patients with NIDDM. Diabetes Care.. 1995;18:681-685.[Abstract]
  54. Perlmuter LC, Nathan DM, Goldfinger Sh, Russo PA, Yates J, Larkin M. Triglyceride levels affect cognitive function in noninsulin-dependent diabetics. J Diabetic Complic.. 1988;2:210-213.[Medline]
  55. Rogers RL, Meyer JS, McClintic K, Morel KF. Reducing hypertriglyceridemia in elderly patients with cerebrovascular disease stabilizes or improves cognition and cerebral perfusion. Angiology.. 1989;50:(4 Pt 1): 260-269.
  56. Atzmon G, Gabriely I, Greiner W, Davidson D, Schechter C, Barzilai N. Plasma HDL levels highly correlate with cognitive function in exceptional longevity. J Gerontol Med Sci.. 2002;57A:M712-M715.
  57. Elias MF, Elias PK, Sullivan LM, Wolf PA, D'Agostino RB. Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int J Obesity.. 2003;27:260-268.[Medline]
  58. McGeer EG, McGeer PL. Inflammatory processes in Alzheimer's disease. Progr Neuro-Psychopharmacol Biol Psychiatry.. 2003;27:741-749.[Medline]
  59. Morley JE. Sex hormones and diabetes. Diabetes Rev.. 1998;6:6-15.
  60. Flood JF, Farr SA, Kaiser FE, Laregina M, Morley JE. Age-related decrease of plasma testosterone in SAMP8 mice—replacement improves age-related impairment of learning and memory. Physiol Behav.. 1995;57:669-673.[Medline]
  61. Morley JE, Kumar VB, Bernardo AE, et al. Beta-Amyloid precursor polypeptide in SAMP8 mice affects learning and memory. Peptides.. 2000;21:1761-1767.[Medline]
  62. Kumar VB, Farr SA, Flood JF, et al. Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice. Peptides.. 2000;21:1769-1775.[Medline]
  63. Banks WA, Farrr SA, Butt W, Kumar VB, Franko MW, Morley JE. Delivery across the blood-brain barrier of antisense directed against amyloid beta: reversal of learning and memory deficits in mice overexpressing amyloid precursor protein. J Pharmacol Exper Ther.. 2001;297:1113-1121.[Abstract/Free Full Text]
  64. Farr SA, Poon HF, Dogrukol-Ak D, et al. The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem.. 2003;84:1173-1183.[Medline]
  65. Rosenthal MJ, Fajardo M, Gilmore S, Morley JE, Naliboff BD. Hospitalization and mortality of diabetes in older adults. A 3-year prospective study. Diabetes Care.. 1998;21:231-235.[Abstract]
  66. Tafet GE, Bernardini R. Psychoneuroendocrinological links between chronic stress and depression. Progr Neuro-Psychopharmacol Biol Psychiatry.. 2003;27:893-903.[Medline]
  67. Fisher A, Morley JE. Antiaging medicine: the good, the bad, and the ugly. J Gerontol Med Sci.. 2002;57A:M636-M639.
  68. Butler RN, Fossel M, Harman SM, et al. Is there an antiaging medicine? J Gerontol Biol Sci.. 2002;57A:B333-B338.
  69. Olshansky SJ, Hayflick L, Carnes BA. Position statement on human aging. J Gerontol Biol Sci.. 2002;57A:B292-B297.
  70. Morley JE, Flaherty JH, Thomas DR. Geriatricians, continuous quality improvement, and improved care for older persons. J Gerontol Med Sci.. 2003;58A:809-812.
  71. Nebeker JR, Hurdle JF, Bair BD. Medical informatics in geriatrics. J Gerontol Med Sci.. 2003;58A:820-825.
  72. Tsilimingras D, Rosen AK. Berlowitz DR. patient safety in geriatrics: a call for action. J Gerontol Med Sci.. 2003;58:813-819.
  73. Hartnell JM, Morley JE, Mooradian AD. Reduction of alkali-induced white blood cell DNA unwinding rate: a potential biomarker of aging. J Gerontol Biol Sci.. 1989;44A:B125-B130.
  74. Evans WJ. Exercise as the standard of care for elderly people. J Gerontol Med Sci.. 2002;57A:M260-M261.
  75. Brandon LJ, Gaasch DA, Boyette LW, Lloyd AM. Effects of long-term resistive training on mobility and strength in older adults with diabetes. J Gerontol Med Sci.. 2003;58:740-745.
  76. Nicklas BJ, Denis KE, Berman DM, Sorkin J, Ryan AS, Goldberg AP. Lifestyle intervention of hypocaloric dieting and walking reduces abdominal obesity and improves coronary heart disease risk factors in obese, postmenopausal, African-American and Caucasian women. J Gerontol Med Sci.. 2003;58:181-189.[Medline]
  77. Singh MAF. Exercise comes of age: rationale and recommendations for a geriatric exercise prescription. J Gerontol Med Sci.. 2002;57A:M262-M282.



This article has been cited by other articles:


Home page
 JAMAHome page
B. J. Willcox, Q. He, R. Chen, K. Yano, K. H. Masaki, J. S. Grove, T. A. Donlon, D. C. Willcox, and J. D. Curb
Midlife Risk Factors and Healthy Survival in Men.
JAMA, November 15, 2006; 296(19): 2343 - 2350.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Services
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
PubMed
Right arrow PubMed Citation

HOME ARCHIVE SEARCH TABLE OF CONTENTS